Froceth

Froceth is a Lithuanian biotechnology company specializing in the development and manufacturing of advanced therapy medicinal products (ATMPs). Founded in 2014, it was the first company in the Baltic region to receive a GMP license for autologous cell therapy production. The company's primary focus is on personalized medicine, offering innovative treatments such as dendritic cell vaccines and cytokine-induced killer (CIK) cells for various oncology indications. Additionally, Froceth provides regenerative medicine solutions, including stromal vascular fraction (SVF) and platelet-rich plasma (PRP) therapies for orthopedic and aesthetic use. The company operates a state-of-the-art manufacturing facility in Vilnius, where it processes patient-specific cells under strict quality standards. Froceth collaborates closely with clinical institutions and research centers to advance the application of cell-based immunotherapies in Europe.